	US 12,186,370 B1
	ACTRIIB ligand trap compositions and uses thereof
Johnson Varghese, Lexington, MA (US); David Mahon, Budd Lake, NJ (US); Nandakumar Madayiputhiya, Scarsdale, NY (US); Kendall Davis Carey, Yardley, PA (US); Promod Kumar Mehndiratta, Chester Springs, PA (US); Ping Carlson, Skillman, NJ (US); and Rajeev Boregowda, Somerset, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by CELGENE CORPORATION, Summit, NJ (US)
Filed on Nov. 4, 2021, as Appl. No. 17/519,305.
Claims priority of provisional application 63/110,331, filed on Nov. 5, 2020.
Int. Cl. A61K 38/17 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01)

CPC A61K 38/179 (2013.01) [A61K 38/1793 (2013.01); C07K 14/71 (2013.01); C07K 14/715 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)]

6 Claims

1. A composition comprising an ActRIIB-Fc fusion protein comprising the amino acid sequence of SEQ ID NO:1, wherein the composition comprises fusion proteins having one or more of the following changes to said amino acid sequence in the following amounts:

a. one or more aspartic acid residues of SEQ ID NO: 1 are isomerized in 0.4% to 0.6% of said fusion proteins; or

b. one or more methionine residues of SEQ ID NO: 1 are oxidized in 0.2% to 1.2% of said fusion proteins.